Funding profile · AI drug discovery

CellType

No Form D has been filed under CellType, Inc.’s own name. What is on the public record so far is three small investor side vehicles that raised money to put into the company, and a Y Combinator batch slot. Here is what the filings show.

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

Reading the filings

1. Nobody has filed a Form D for CellType, Inc. itself.All three filings on record are for Sydecar administered LLC series named after CellType, the standard structure for a special purpose vehicle that pools smaller checks into one line on a company’s cap table. None was filed by an entity called CellType, Inc. That can mean CellType’s own round has not closed, that it raised under an exemption that does not require a Form D, or that a filing has simply not been made yet. It does not mean no money has moved.
2. The three vehicles read as three separate angel pools, not one round.They are named for different windows, March 2026, April 2026, and a plain “CGF2021” series, and they raised different amounts from different sized investor groups: 5 investors averaging about $31,400, 3 investors averaging about $34,800, and 21 investors averaging about $60,800. That spread of dates and group sizes looks like several separate syndicates rolling money in over about a month, not one coordinated tranche.
3. All three declined to state a total offering size.Every filing lists the total offering amount as indefinite. That is common for SPVs, which are often sized to whatever the syndicate can raise, but it means the $1,537,878 sold across the three vehicles is a floor, not a target.
4. One administrator ties all three together.Sydecar LLC, at the same Claymont, Delaware address, administers all three filings, and Brett Sagan signs all three as an officer of the administrator. This is a fund administration platform used by many unrelated SPVs, so common administration says nothing about who organized any individual syndicate.
5. The company’s own funding claims are not on this record.CellType’s public materials describe interest from “Top 10 pharma” and a Pioneer Fund general partner has spoken publicly about backing the company, but no priced round, valuation, or total raised has been disclosed in any source reviewed for this profile.

Commercial signals

What to watch

• A Form D filed directly under CellType, Inc.’s own name, which would disclose an actual round size and lead investors.
• Whether the Senhwa MOU converts into a signed licensing, co-development, or joint venture agreement with disclosed terms.
• Whether any of the “Top 10 pharma” relationships are named.
• Additional Sydecar or other SPV filings, which would mark further angel fundraising activity even without a company level Form D.

The CellType story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Ditto Biosciences: Shared investor: Independent Pioneer Fund. A three person company mining the genomes of viruses, ticks and worms for proteins that already know how to calm the human immune system
• Dropprint Genomics: Also in Drug Discovery and Delivery. A San Francisco startup that built computational infrastructure and a database of over a million immune cells to make single cell genomics cheaper to run
• CellChorus: Also in Drug Discovery and Delivery. A University of Houston spinout that films immune cells one at a time and scores how well each one kills
• Exonic: Also in Drug Discovery and Delivery. A three person San Francisco startup built on a bet that biological AI models trained on messy, unstructured data can be combined on an open, no code platform and turn

Sources

1. Public recordForm D, CellType a Series of CGF2021 LLCSEC EDGAR, CIK 0002127136 · filed Apr 14, 2026
2. Public recordForm D, CELLTYPE B311 Mar 2026 a Series of CGF2021 LLCSEC EDGAR, CIK 0002129557 · filed Apr 17, 2026
3. Public recordForm D, MA7 CellType Apr 2026 a Series of CGF2021 LLCSEC EDGAR, CIK 0002130855 · filed May 11, 2026
4. Public recordEDGAR company search, filings matching “CellType,” Form DSEC EDGAR · accessed Sep 2026
5. CompanyCellType: The agentic drug company (Y Combinator company page and launch post)Y Combinator · Oct 14, 2025
6. IndependentCellType Uses AI to Simulate Human Biology for Drug DiscoveryThe Silicon Valley Post · Mar 24, 2026
7. IndependentY Combinator Backs Yale Spinout Using Agentic AI to De-risk Clinical TrialsBiopharmaTrend, Anastasiia Rohozianska · Feb 19, 2026
8. PartnerSenhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellTypeCision PR Newswire, Senhwa Biosciences · Mar 3, 2026
9. IndependentHow a Gemma model helped discover a new potential cancer therapy pathwayGoogle, Shekoofeh Azizi and Bryan Perozzi · Oct 15, 2025
10. IndependentPioneer Fund Future of Health, portfolio pagehealth.pioneerfund.vc · accessed 2026

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in CellType. This page is not an offer to sell or a recommendation to buy any security.